ArticleFrontiers in aging neuroscience2026
Unraveling the role of HIF-1 in peripheral blood mononuclear cells from older patients with Alzheimer's disease.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cerebrovascular damage is increasingly recognized as an early event in the dementia continuum, occurring before typical Alzheimer's disease (AD) pathological changes. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor composed of HIF-1α and HIF-1β subunits which, under hypoxic conditions, dimerize and activate hypoxia response element (HRE)-containing genes. HIF-1α has been reported to be implicated in neuroinflammation, a key feature of AD. Methods: This study evaluated HIF1A and its negative regulator HIF1AN gene expression in peripheral blood mononuclear cells (PBMCs) from 308 cognitively healthy older individuals (controls) and 83 AD patients, and their associations with gene expression of HRE-containing inflammatory genes in PBMCs and corresponding protein concentrations in plasma. Results: Peripheral blood mononuclear cells from AD patients showed lower gene expression of both HIF1A and HIF1AN compared with controls, and this reduction was associated with higher odds of AD. In the overall cohort, after adjustment for age, sex, Apolipoprotein E ε4 status, and diagnosis, HIF1A gene expression was positively associated with interleukin (IL)-6, IL-10, tumor necrosis factor-α (TNF-α), IL-1B, and triggering receptor expressed on myeloid cells-1 (TREM-1) gene expression, whereas HIF1AN gene expression was negatively associated with IL-6, IL-1B, and TREM-1 gene expression. Furthermore, HIF1A gene expression was positively associated with plasma IL-1β and soluble TREM-1 concentrations, while HIF1AN gene expression was negatively associated with IL-10 concentrations. Discussion: Overall, these findings support the use of peripheral cells to investigate HIF-1 pathway dysregulation in AD and suggest that altered HIF-1α signaling may reflect impaired cellular responsiveness linked to neuroinflammatory processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.